BiOrion is Drug Discovery in Netherlands that focus on domain antibodies business. Founded in 2007. They cover business area such as developer, therapeutic and imaging diagnostic, patient, fibrotic disease, bicyclic peptide, single domain antibody, ?-receptor, lung fibrosis, cardiac fibrosis, kidney fibrosis, hepatic fibrosis, healthcare professional, high medical need, urgency.
2007
( 17 years old in 2024 )
Domain Antibodies
-
MediTech Center, Healthy Ageing Campus
L.J. Zielstraweg 1
9713 GX Groningen
Netherlands
Private
developertherapeutic and imaging diagnosticpatientfibrotic diseasebicyclic peptidesingle domain antibody?-receptorlung fibrosiscardiac fibrosiskidney fibrosishepatic fibrosishealthcare professionalhigh medical needurgency
* We use standard office opening hours in near BiOrion's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
BiOrion is Drug Discovery business from Netherlands that founded in 2007 (17 years old in 2024), BiOrion business is focusing on Domain Antibodies.
BiOrion headquarter office and corporate office address is located in MediTech Center, Healthy Ageing Campus L.J. Zielstraweg 1 9713 GX Groningen Netherlands.
BiOrion was founded in Netherlands.
In 2024, BiOrion is currently focus on domain antibodies sector.
Above is snippet of Google Trends for "domain antibodies" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with BiOrion, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
